China Resources Double-Crane Pharmaceutical Co Ltd (600062) — Cash Flow Reinvestment Rate
China Resources Double-Crane Pharmaceutical Co Ltd (600062) has a Cash Flow Reinvestment Rate of 0.39x as of September 2025, reinvesting CN¥192.28 Million (capex CN¥192.28 Million ) from operating cash flow of CN¥487.90 Million. See 600062 cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
China Resources Double-Crane Pharmaceutical Co Ltd Cash Flow Reinvestment Rate (1999–2024)
Historical reinvestment intensity for China Resources Double-Crane Pharmaceutical Co Ltd across 26 annual periods. For the full cash flow conversion analysis, see cash flow conversion of China Resources Double-Crane Pharmaceuti.
Annual Cash Flow Reinvestment Rate for China Resources Double-Crane Pharmaceutical Co Ltd (1999–2024)
Year-by-year capital reinvestment analysis for China Resources Double-Crane Pharmaceutical Co Ltd. See 600062 financial flexibility score to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (CNY) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 0.50x | CN¥905.94 Million | CN¥1.83 Billion | CN¥637.50 Million | ▼ -37.0% |
| 2023 | 0.79x | CN¥1.30 Billion | CN¥1.65 Billion | CN¥614.31 Million | ▼ -48.0% |
| 2022 | 1.51x | CN¥2.03 Billion | CN¥1.34 Billion | CN¥525.53 Million | ▲ +203.6% |
| 2021 | 0.50x | CN¥669.03 Million | CN¥1.34 Billion | CN¥491.67 Million | ▲ +34.3% |
| 2020 | 0.37x | CN¥505.32 Million | CN¥1.36 Billion | CN¥348.09 Million | ▼ -46.7% |
| 2019 | 0.70x | CN¥1.00 Billion | CN¥1.44 Billion | CN¥241.65 Million | ▲ +71.0% |
| 2018 | 0.41x | CN¥598.40 Million | CN¥1.47 Billion | CN¥228.69 Million | ▼ -18.4% |
| 2017 | 0.50x | CN¥592.58 Million | CN¥1.19 Billion | CN¥154.82 Million | ▲ +40.8% |
| 2016 | 0.35x | CN¥273.34 Million | CN¥771.25 Million | CN¥110.04 Million | ▼ -4.8% |
| 2015 | 0.37x | CN¥260.99 Million | CN¥701.35 Million | CN¥168.49 Million | ▲ +87.8% |
| 2014 | 0.20x | CN¥142.38 Million | CN¥718.38 Million | CN¥142.38 Million | ▼ -50.3% |
| 2013 | 0.40x | CN¥217.68 Million | CN¥546.24 Million | CN¥217.68 Million | ▼ -28.9% |
| 2012 | 0.56x | CN¥221.89 Million | CN¥396.05 Million | CN¥221.89 Million | ▼ -15.4% |
| 2011 | 0.66x | CN¥338.78 Million | CN¥511.53 Million | CN¥338.78 Million | ▼ -8.8% |
| 2010 | 0.73x | CN¥370.18 Million | CN¥509.67 Million | CN¥370.18 Million | ▼ -12.9% |
| 2009 | 0.83x | CN¥285.16 Million | CN¥342.01 Million | CN¥285.16 Million | ▼ -10.6% |
| 2008 | 0.93x | CN¥309.20 Million | CN¥331.71 Million | CN¥309.20 Million | ▲ +61.2% |
| 2007 | 0.58x | CN¥136.17 Million | CN¥235.46 Million | CN¥136.17 Million | ▲ +2.3% |
| 2006 | 0.57x | CN¥171.66 Million | CN¥303.71 Million | CN¥171.66 Million | ▼ -37.9% |
| 2005 | 0.91x | CN¥127.13 Million | CN¥139.78 Million | CN¥127.13 Million | ▲ +109.7% |
| 2004 | 0.43x | CN¥196.84 Million | CN¥453.72 Million | CN¥196.84 Million | ▼ -82.8% |
| 2003 | 2.52x | CN¥375.98 Million | CN¥148.94 Million | CN¥375.98 Million | ▲ +40.9% |
| 2002 | 1.79x | CN¥251.99 Million | CN¥140.63 Million | CN¥251.99 Million | ▲ +43.9% |
| 2001 | 1.25x | CN¥175.58 Million | CN¥141.01 Million | CN¥175.58 Million | ▲ +147.8% |
| 2000 | 0.50x | CN¥86.83 Million | CN¥172.81 Million | CN¥86.83 Million | ▼ -5.4% |
| 1999 | 0.53x | CN¥69.86 Million | CN¥131.54 Million | CN¥69.86 Million | — |